ArticleBMC neurology2026
Clinical outcomes of a generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: a nationwide retrospective cohort study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStroke is a leading cause of death and disability worldwide. Clopidogrel, an antiplatelet agent that is commonly used for the secondary prevention of ischemic stroke, yet the data on the efficacy and safety of generic versus brand-name clopidogrel remain limited. The aim of this retrospective cohort study was to compare the efficacy and safety of a specific generic formulation of clopidogrel (Thrombifree) with brand-name clopidogrel during the long-term monotherapy phase, initiated ≥ 91 days after hospital discharge, in the secondary prevention of ischemic stroke.
methodsPatients with ischemic stroke prescribed either generic or brand-name clopidogrel were identified from the Taiwan National Health Insurance Research Database between 2008 and 2021. The efficacy was defined as recurrent ischemic stroke and safety as major bleeding. Possible confounding effects were reduced using 1:1 propensity score matching.
resultsA total of 5,540 matched pairs were included in the analysis. The incidence rate of recurrent ischemic stroke was 3.95 per 100 person-years in the generic group, and 3.43 per 100 person-years in the brand-name group (subdistribution hazard ratio [SHR] 1.09, 95% confidence interval [CI] 0.97–1.21). The risk of major bleeding was also similar between the two groups. No significant differences were observed in other secondary cardiovascular or bleeding endpoints.
conclusionThis study showed that the specific generic clopidogrel formulation evaluated in this study demonstrated similar efficacy and safety profiles compared with the brand-name product in patients with ischemic stroke, with no statistically significant differences observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.